# Prioritization and Bioactivity Characterization of Novel Bile Acids Produced by the Microbiome

> **NIH NIH R01** · MICHIGAN STATE UNIVERSITY · 2024 · $637,000

## Abstract

Project Summary – Through 170 years of bile acid (BA) chemistry research, our knowledge of
mammalian BA conjugation was limited to the amino acids glycine and taurine. Our group recently
discovered that the gut microbiome can also conjugate BAs with a wide variety of amino acids, which
has changed our fundamental understanding of BA biochemistry. These compounds are called
‘microbially conjugated bile acids’ (MCBAs), they are common in humans, particularly those with
inflammatory bowel disease, and are at similar concentrations to other host-produced BAs making them
physiologically relevant. Furthermore, we recently discovered they are made by unrecognized
transferase activity of the bacterial enzyme bile salt hydrolase (BSH/T), which itself has been studied
for decades. Here we will explore how MCBAs are made by the microbiome and how their signaling
properties can alter disease outcomes in a mouse model of gut inflammation.
 In our preliminary data, we show myriad gut bacteria produce MCBAs and we have evidence
that there is selective pressure on the BSH/T for its acyl-transfer properties. In controlled murine and
cell culture experiments, we show that MCBAs agonize gut BA receptors such as FXR and TGR5, which
can alter inflammatory signaling properties in gut epithelial cells. Analysis of human samples shows that
MCBAs are at physiologically relevant concentrations in the gut and can enter circulation. Therefore,
we believe MCBAs contribute to host-microbiome crosstalk with potential implications for gut health.
We also show that BA conjugation by the host is important for overall health in the mouse DSS-model
of gut inflammation. This proposal will therefore test the hypothesis that MCBAs alter can alter disease
outcomes in the DSS-model due to their bioactivity which is dependent on the specific amino acid
conjugated. We will use a diverse approach including microbiology, cell receptor assays, and a knockout
mouse model that lacks host-BA conjugation to understand the role of these compounds in GI health.
 We have three principle aims: 1) Define the microbiology of MCBA production and their
resistance to subsequent hydrolysis, 2) Determine their agonist activity on the ileal receptor FXR in vitro
and in vivo, and 3) Show that MCBAs affect outcomes in the DSS-model of GI inflammation using BA
conjugation knockout and wildtype mice. Michigan State provides all the resources needed to complete
the project and the PI has assembled an integrative team with broad expertise. This project will explore
the basic science of MCBAs creating a platform for research on their impacts on human health. If we
can better understand the signaling and physiological role of MCBAs they could be developed as drugs
to treat myriad GI diseases. Results from this project will further emphasize the importance of the
chemical crosstalk between us and our microbiome for maintaining human health.

## Key facts

- **NIH application ID:** 10954001
- **Project number:** 1R01DK140854-01
- **Recipient organization:** MICHIGAN STATE UNIVERSITY
- **Principal Investigator:** Robert Andrew Quinn
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $637,000
- **Award type:** 1
- **Project period:** 2024-08-01 → 2029-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10954001

## Citation

> US National Institutes of Health, RePORTER application 10954001, Prioritization and Bioactivity Characterization of Novel Bile Acids Produced by the Microbiome (1R01DK140854-01). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10954001. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*